The Food and Drug Administration on Thursday approved Gilead Sciences’ antiviral drug remdesivir as a treatment for the coronavirus.
In May, the FDA granted the drug an emergency use authorization, allowing hospitals and doctors to use the drug on patients hospitalized with the disease even though the drug has not been formally approved by the agency. The intravenous drug has helped shorten the recovery time of some hospitalized Covid-19 patients.
Remdesivir is now the first and only fully approved treatment in the U.S. for Covid-19, which has infected more than 41.3 million and killed more than 1 million, according to data compiled by Johns Hopkins University.
“Since the beginning of the COVID-19 pandemic, Gilead has worked relentlessly to help find solutions to this global health crisis,” Gilead CEO Daniel O’Day said in a statement. “It is incredible to be in the position today, less than one year since the earliest case reports of the disease now known as COVID-19, of having an FDA-approved treatment in the U.S. that is available for all appropriate patients in need.”